Insider Buying: Attovia Therapeutics (NASDAQ:ATTO) Director Purchases 500,000 Shares

Posted by Anthony Miller on Aug 13th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh bought 500,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the transaction, the director directly owned 3,020,632 shares of the company’s stock, valued at $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Colin Walsh also recently made the following trade(s):

On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The stock was sold at an average price of $21.28, for a total transaction of $2,251,572.96.

Attovia Therapeutics Trading Up 6.2%

Attovia Therapeutics stock traded up $1.12 during trading on Thursday, hitting $19.18. The company had a trading volume of 406,507 shares, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 1-year low of $16.15 and a 1-year high of $22.79.

Institutional Investors Weigh In On Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. boosted its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.